African Trypanosomiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
African Trypanosomiasis Pipeline Drugs Market Overview
African Trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable), sweating, swollen lymph nodes all over the body, swollen, red, painful nodule at site of fly bite and weakness.
The African Trypanosomiasis – drugs in development research report provides a comprehensive overview on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects.
Key Targets in the African Trypanosomiasis Pipeline Drugs Market
The key targets in the African Trypanosomiasis pipeline drugs market are Glycylpeptide N Tetradecanoyltransferase, Adenosylmethionine Decarboxylase, Lanosterol 14 Alpha Demethylase, Proteasome, Purinergic Receptor P2X, Purinergic Receptor P2Y, Trypanosoma brucei ATP Dependent 6-Phosphofructokinase, Trypanosoma brucei Cysteine Protease.
African Trypanosomiasis Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the African Trypanosomiasis Pipeline Drugs Market
The key mechanisms of action in the African Trypanosomiasis pipeline drugs market are Glycylpeptide N Tetradecanoyltransferase Inhibitor, Adenosylmethionine Decarboxylase Inhibitor, Lanosterol 14 Alpha, Demethylase Inhibitor, Proteasome Inhibitor, Purinergic Receptor P2X Antagonist, Purinergic Receptor P2Y Antagonist, Trypanosoma brucei ATP Dependent 6-Phosphofructokinase Inhibitor, and Trypanosoma brucei Cysteine Protease Inhibitor.
African Trypanosomiasis Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
African Trypanosomiasis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the African Trypanosomiasis pipeline drugs market are Oral, and Intravenous.
African Trypanosomiasis Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the African Trypanosomiasis Pipeline Drugs Market
The key molecule types in the African Trypanosomiasis pipeline drugs market are Small Molecule, and Peptide.
African Trypanosomiasis Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the African Trypanosomiasis Pipeline Drugs Market
The major companies in the African Trypanosomiasis pipeline drugs market are Cesa Alliance SA, F.Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, MediSynergics LLC, Novartis AG, Paxmedica Inc, Pfizer Inc, Sanofi, Scynexis Inc, and Synstar Japan Co Ltd.
African Trypanosomiasis Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
African Trypanosomiasis Pipeline Drugs Market Overview
Key Targets | Glycylpeptide N Tetradecanoyltransferase, Adenosylmethionine Decarboxylase, Lanosterol 14 Alpha Demethylase, Proteasome, Purinergic Receptor P2X, Purinergic Receptor P2Y, Trypanosoma brucei ATP Dependent 6-Phosphofructokinase, Trypanosoma brucei Cysteine Protease |
Key Mechanisms of action | Glycylpeptide N Tetradecanoyltransferase Inhibitor, Adenosylmethionine Decarboxylase Inhibitor, Lanosterol 14 Alpha, Demethylase Inhibitor, Proteasome Inhibitor, Purinergic Receptor P2X Antagonist, Purinergic Receptor P2Y Antagonist, Trypanosoma brucei ATP Dependent 6-Phosphofructokinase Inhibitor, and Trypanosoma brucei Cysteine Protease Inhibitor |
Key Routes of Administration | Oral, and Intravenous |
Key Molecule Types | Small Molecule, and Peptide |
Major Companies | Cesa Alliance SA, F.Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, MediSynergics LLC, Novartis AG, Paxmedica Inc, Pfizer Inc, Sanofi, Scynexis Inc, and Synstar Japan Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of African Trypanosomiasis
- The pipeline guide reviews pipeline therapeutics for African Trypanosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in African Trypanosomiasis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates African Trypanosomiasis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for African Trypanosomiasis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for African Trypanosomiasis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
MediSynergics LLC
Novartis AG
Paxmedica Inc
Pfizer Inc
Sanofi
Scynexis Inc
Synstar Japan Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the African Trypanosomiasis pipeline drugs market?
The key targets in the African Trypanosomiasis pipeline drugs market are Glycylpeptide N Tetradecanoyltransferase, Adenosylmethionine Decarboxylase, Lanosterol 14 Alpha Demethylase, Proteasome, Purinergic Receptor P2X, Purinergic Receptor P2Y, Trypanosoma brucei ATP Dependent 6-Phosphofructokinase, Trypanosoma brucei Cysteine Protease.
-
What are the key mechanisms of action in the African Trypanosomiasis pipeline drugs market?
The key mechanisms of action in the African Trypanosomiasis pipeline drugs market are Glycylpeptide N Tetradecanoyltransferase Inhibitor, Adenosylmethionine Decarboxylase Inhibitor, Lanosterol 14 Alpha, Demethylase Inhibitor, Proteasome Inhibitor, Purinergic Receptor P2X Antagonist, Purinergic Receptor P2Y Antagonist, Trypanosoma brucei ATP Dependent 6-Phosphofructokinase Inhibitor, and Trypanosoma brucei Cysteine Protease Inhibitor.
-
What are the key routes of administration in the African Trypanosomiasis pipeline drugs market?
The key routes of administration in the African Trypanosomiasis pipeline drugs market are Oral, and Intravenous.
-
What are the key molecule types in the African Trypanosomiasis pipeline drugs market?
The key molecule types in the African Trypanosomiasis pipeline drugs market are Small Molecule, and Peptide.
-
What are the major companies in the African Trypanosomiasis pipeline drugs market?
The major companies in the African Trypanosomiasis pipeline drugs market are Cesa Alliance SA, F.Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, MediSynergics LLC, Novartis AG, Paxmedica Inc, Pfizer Inc, Sanofi, Scynexis Inc, and Synstar Japan Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.